# Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-envafolimab-plus-lenvatinib-combined-with-tace-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tingbo Liang,Yiwen Chen,Xin Huang,Wendi Hu,Xiang Li,Junhui Sun,Yan Shen,Min Zhang,Jian Wu,Shunliang Gao,Jun Yu,Risheng Que,Yun Zhang,Fuchun Yang,Weiliang Xia,Aibin Zhang,Xiaofeng Tang,Xueli Bai |
| Citations | 3 |
| DOI | 10.1200/jco.2023.41.4_suppl.558 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4317863198 |
| Type | conference-abstract |
| Year | 2023 |

## Paper authors

- [Xin Huang](https://scholariq.org/researchers/xin-huang/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.